» Articles » PMID: 37501860

Efficiency of Biobran/MGN-3, an Arabinoxylan Rice Bran, in Attenuating Diabetes-Induced Cognitive Impairment of the Hippocampus Via Oxidative Stress and IR/Akt/NF-B in Rats

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Type 2 diabetes mellitus (T2DM) is a common metabolic disease accompanied by cognitive impairment, hippocampal malfunctioning, and inflammation. Biobran/MGN-3, an arabinoxylan rice bran, has been shown to have an antidiabetic effect in streptozotocin-induced diabetic rats. The present study investigates Biobran's effect against diabetes-induced cognitive impairment and synaptotoxicity in the hippocampus via oxidative stress and the IR/A/NF-B signaling pathway in rats. Diabetes was induced via i.p. injection of streptozotocin (STZ) (40 mg/kg BW); STZ-treated rats were then administered Biobran (100 mg/kg BW) for 4 wks. Biobran supplementation improved motor coordination and muscular strength, as assessed by Kondziella's inverted screen test. Biobran also improved concentration levels of glutathione (GSH), antioxidant enzymes, acetylcholine (ACh), dopamine, serotonin, insulin receptor (IR), and alpha serine-threonine protein kinase (Akt); it protected against elevated levels of glucose, total cholesterol, triglycerides, oxidative stress markers, TBARS, NO, AChE, and MAO; and it significantly decreased inflammatory cytokines levels of IL-1, NF-B, TNF-, and amyloid . Moreover, Biobran ameliorated hippocampal histological alterations. Immunohistochemical observations showed that Biobran reduced overexpression of hippocampal synaptophysin and Ki67 relative to untreated diabetic rats. Biobran may ameliorate hippocampal alterations in diabetic rats via its antidiabetic, antiproliferative, anti-inflammatory, antiapoptotic, and antioxidant effects.

Citing Articles

Use of the Hyperbaric Chamber Versus Conventional Treatment for the Prevention of Amputation in Chronic Diabetic Foot and the Influence on Fitting and Rehabilitation: A Systematic Review.

Apolo-Arenas M, Guerrero-Nogales L, Diaz-Munoz C, Caro-Puertolas B, Parraca J, Cana-Pino A Int J Vasc Med. 2025; 2024:8450783.

PMID: 39764384 PMC: 11703574. DOI: 10.1155/ijvm/8450783.

References
1.
Ekakitie L, Oyinloye B, Ajiboye B . The ameliorative activity of in streptozotocin-induced type II diabetes mellitus rat model. Heliyon. 2021; 7(4):e06596. PMC: 8056426. DOI: 10.1016/j.heliyon.2021.e06596. View

2.
Ho N, Sommers M, Lucki I . Effects of diabetes on hippocampal neurogenesis: links to cognition and depression. Neurosci Biobehav Rev. 2013; 37(8):1346-62. PMC: 3788092. DOI: 10.1016/j.neubiorev.2013.03.010. View

3.
Kondziella W . [A NEW METHOD FOR THE MEASUREMENT OF MUSCLE RELAXATION IN WHITE MICE]. Arch Int Pharmacodyn Ther. 1964; 152:277-84. View

4.
Chaudhury A, de Miranda-Neto M, Pereira R, Zanoni J . Myosin Va but Not nNOSα is Significantly Reduced in Jejunal Musculomotor Nerve Terminals in Diabetes Mellitus. Front Med (Lausanne). 2015; 1:17. PMC: 4335397. DOI: 10.3389/fmed.2014.00017. View

5.
Li W, Risacher S, Gao S, Boehm 2nd S, Elmendorf J, Saykin A . Type 2 diabetes mellitus and cerebrospinal fluid Alzheimer's disease biomarker amyloid β1-42 in Alzheimer's Disease Neuroimaging Initiative participants. Alzheimers Dement (Amst). 2017; 10:94-98. PMC: 5725206. DOI: 10.1016/j.dadm.2017.11.002. View